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INTRODUCTION
Implant is a contraceptive device that is placed under
the skin, containing steroid hormones and are used
for a long time; one of them is the levonorgestrel im-
plants.
Levonorgestrel (hereinafter abbreviated as LNG) is
a progestogen and is a bioactive material which is
currently widely used for contraceptive development,
both for the contraceptive pill, injection, IUD (Intra
Uterine Device), and implant.1,2
History of Implant
History of Implant in the World
In 1964 Folkman and Long published their findings
about silastic tube containing a drug that can slowly
release it for long periode of time. Two years later,
Dziuk and Cook found silastic capsules that can re-
lease the drug in vitro with a constant concentration.
Segal and Croxatto incorporated these principles by
inserting some steroid hormones into the tube. Ap-
parently silastic capsule containing a steroid hormone
inserted under the skin can release the hormone more
than one year. The results of this preliminary research
into the basic concept of the development of long-
term contraception under the skin (implant).3-5
First subdermal implant clinical trial began in 1968
in Santiago, Chile. This implant tube contained poly-
dimethylsiloxane (silastic or silicon), which was filled
chlormadinon acetate, a synthetic gestagen or proges-
tin. But clinical trials have failed and no longer con-
tinued because chlormadinon acetate turned out to be
toxic in animal experiments.6
Subsequently, from 1970 to 1978 series of clinical
trials of single rod implant up to six rods containing
megestrol acetate were carried out in Chile, India and
Brazil. The emphasis of study was about how long
the implant worked and how many implants should
be inserted. However, these clinical trials was not
continued because of contraceptive failure of ectopic
pregnancy in some subjects. Pregnancy was suspected
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because the levels of megestrol acetate was not strong
enough to inhibit ovulation. Megestrol acetate was
also associated with higher incidence of adnexal tu-
mor and fetal heart abnormalities in the use of high
doses for the treatment of abortion.4,7
In 1974 implant containing noretindron, norges-
trienon, and levonorgestrel was used. Experiments
using the implant that contained four to six implants
noretindron were also not encouraging either. 21 preg-
nancies from 112 women in one year the use of im-
plants were reported. Instead the six-implant clinical
trials using levonogestrel and norgestrienon could
prevent pregnancy better with retention rates higher
usage, because after the implant was inserted anovu-
latoar menstrual cycle for several months would be
obtained.4,7-8
Phase 3 clinical trials of LNG implant consisting of
six capsules compared with the IUD was first per-
formed in 1975 in six countries, Brazil, Chile, Den-
mark, Dominican Republic, Finland, and Jamaica. The
results of this clinical trial demonstrated a low preg-
nancy rate (0.6 per 100 women a year), good received
and high used survival rate (75 - 80%).9,10 The results
report of the first 5 years of research in the early years
1980 indicated that the LNG implants were well re-
ceived and very few side effects.11 Later in the year
1980 - 1982 conducted further phase 3 clinical trials in
eight countries Colombia, Ecuador, Egypt, India, Indo-
nesia, Sweden, Thailand, and USA.12
In 1982 a preliminary study comparing six LNG
implant with two LNG implants was conducted in the
Dominican Republic, Sweden, Chile, Finland, and
USA. This research was delayed because of problems
in the manufacture of implant. In 1983, Leiras Phar-
maceuticals, Huhtamaki Oy, Turku, Finland was ap-
pointed to make and market the LNG implant Nor-
plant®. Norplant® consists of six capsules. Each 36
mg capsule LNG as an ingredient, with capsule dia-
meter 2.4 mm and 3.4 cm long. Finland is the first
country to receive and use Norplant® as a method of
contraception.13
In 1984 - 1985 Norplant® was studied in Bangla-
desh, China, Nepal, Philippines, Singapore, Sri Lanka,
Ghana, Kenya, Nigeria, Haiti, and Zambia. In 1985,
Sweden is the second country to receive and use Nor-
plant®. Furthermore, in 1986 Indonesia, Thailand,
Ecuador and the Dominican Republic also using Nor-
plant® for Family Planning.14
Actually, 1980 was the start of the development
and testing of the implant LNG mainly to the number
of implants that will be installed. At that time implant
was developed which consisted of two rods (Nor-
plant-2®). Each rod implant was 1 cm longer than
Norplant® capsules and contain the LNG is almost
two times more. Norplant® capsule contains 36 mg
of LNG while each rod Norplant-2® contains 75 mg
of LNG.15
In early 1983, basic research on Norplant® has
been completed but the research on the system 2
sticks (Norplant-2®) should be continued, because at
that time the manufacture of elastomeric implant 2
sticks was not available in the market. A few years
later (mid 1990) rod implant with a new elastomer
that is softer and is known by the name Jadelle® (in
America) or Jadena® (in Indonesia) became available.
Later clinical trials comparing implant capsule and
implant 6 - 2 sticks, continued. As a result, Jadelle®
has been recognized by the FDA in 1996,15,16 and
Leiras-Finland started to market in 2001.
Implant technology has been changed since this
contraceptive method was first introduced in 1983.
Implant tubes in use today are made from silicone
elastomers, making it softer and more flexible, be-
cause a lower silicone content.17 The progress of
these technologies led to improve effectiveness as a
contraceptive implant and affect long-term lower
pregnancy rates.18 This depends on the type of con-
traceptive progestins and type of polymer used.19-21
Since 2002 Norplant® is not used anymore in the
United States. Wyeth has discontinued distribution of
Norplant® for prosecution issues related to technical
difficulties in extraction due to the lack of trained
health personnel, although still used in other coun-
tries.22 Outside the United States, Schering still dis-
tributing Norplant® to the world. It is still used by
millions of women in developing countries and China.
Instead of Norplant®, there is a second-generation
implant, Jadelle®, which consists of two rods. Jadel-
le® also developed by the Population Council and ma-
nufactured by Leiras Oy, and now by Schering AG,
with the aim of reducing the number of implants
placed. The system is made of elastomer with en-
hanced drug release capability. Therefore, two rods
Jadelle® implants have the same ability in a release
of LNG as the six capsule Norplant®. Jadelle® has
been approved for use for five years in the USA and
Europe; in Indonesia is used for three years,18,23-25
with a cumulative pregnancy rate over the past five
years is 1%.26 Both the Norplant® and Jadelle® has
the same work mechanism to prevent ovulation and
thick the cervical mucus.27
By the year 2000 an Organon (Oss, The Nether-
lands) developed a new technology that is the only
implant contain one rod, containing a different pro-
gestin that is Etonogestrel (ENG), with the name of
Implanon®. This implant into the international market
in 1998 and received by the FDA in 2004. Implanon®
effectives for three years, with the main mechanism
of action is inhibition of ovulation.28 Until 2006, Im-
planon® is registered in more than 40 Asian and Euro-
pean countries as well as in the United States and has
been used by more than 2.5 million women. Cur-
rently, Implanon® is the only implant that is still used
in USA.22,29,30
Other implant types, such as implant Nestorone®
(Elkometrine®), Uniplant®, and Capronor®, or other
implant that consists of a different progestin, biode-
gradable rod, pellets, and the microcapsules are still
under development. Nestorone®, and Uniplant® (con-
taining nomegestrol acetate), is a non-estrogenic pro-
gestin and non-androgenic inactive when given orally
but is more potent than LNG when given by way of
non-oral.31 Capronor®, an implant of a biodegradable
capsule LNG (non silastik). This implant, release of
LNG over 12 - 18 months.32-34
In summary, various methods such implants are
used by many women who want to delay pregnancy
for several years or have enough children and do not
plan to become pregnant again. The main advantage
of this method is the high level of success and the
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long period of usage without any compliance issues.
However, the need for availability of skilled health
services and trained for insertion and removal of im-
plants and the issue of frequent side effects of bleed-
ing, are the main disadvantages of this implant con-
traceptive method.
History of Implant in Indonesia
Norplant® was first introduced and studied in Indo-
nesia in May 1981. Early clinical trials done in Jakarta
and Bandung. Later in September 1982 they con-
ducted in eleven research centers spread across Indo-
nesia with a total sample of 8681 subjects. The results
are quite safe as Norplant® contraceptive. In 1986
Norplant® is accepted and used as one method of con-
traception in Indonesia.4
About 10 years later, in March 1992 there have
been more than 1.25 million users of Norplant® ac-
ceptors throughout Indonesia, and until March 1999
increased to 2,882,889 acceptor implant or a 10.8%
of all contraceptive acceptors in Indonesia totaling
26,729. 030 acceptors. On the other hand, in foreign
countries, up to August 1997 Norplant® has been ap-
proved and used as one of choice of contraceptive
methods by about 60 countries, and today more than
70 million women worldwide have used Norplant® as
a contraceptive.35,36
First-generation implant, Norplant®, developed by
Pupulation Council, New York, USA, and originally
produced by Leiras Oy in Finland, consists of six cap-
sules containing LNG in a matrix of silicone elas-
tomer. Second-generation implant, Jadelle® or Jade-
na®, consisting of two sticks were also developed by
the Population Council and manufactured by Leiras
Oy, but now manufactured by Schering AG, with the
aim of reducing the number of implants placed.
Jadena® Clinical Research in Indonesia is carried out
in 1998 with the same effectiveness and acceptance
of Norplant®, but is faster and easier to insert and
remove it out.37
Implanon®, a single rod implant with bioactive ma-
terials Etonogestrel (3-keto-desogestrel), was investi-
gated in Indonesia in 1998. The result was quite ef-
fective as a contraceptive for three years, was safe
and well received.38,39
Overview of Implant
Since the first discovery of a progestin as a contra-
ceptive implant and scientifically published by Cro-
xatto 1969, and recognition of first-generation implant
Norplant® in Finland in 1983, then the next several
types of implants KB has been developed, researched
and some have been registered and marketed. Until
now it is estimated that implant has been used as a
method of contraception in some 60 countries. More
than 70 million women worldwide have used the im-
plant as their contraception.40
Today implant research and development are aimed
at 4 different types of progestin: levonorgestrel, eto-
nogestrel, nestorone, and nomegestrol acetate, and 2
types of non-biodegradable polymer mixtures and bio-
degradeble. Some of these implants have been mar-
keted and the others were still in the research.27 Im-
plant was placed under the skin on the inner arm be-
tween the biceps and triceps through the puncture
trokar after previously cleaned and given a local an-
esthetic. Furthermore, the active ingredient progestin
released slowly, little by little until the end of life, 6
months to 5 years depending on the type of implant.27
Implant Levonorgestrel
LNG is a progestin that is widely used as active in-
gredients implant, Norplant® and Jadelle® Norplant®
capsule and comprises six Jadelle® comprises 2 rods.
Implant containing a mixture of steroids and polymer,
and capsules containing crystalline steroid implants
only. Both two types of implants are releasing LNG
in the same amount for a period of 5 years. LNG
levels in the blood rises rapidly within the first month
after insertion, and then declined slowly until the end
of useful life. The number of LNG levels depending
on body weight acceptors.41,42 At the end of the fifth
year of usage, LNG levels still remains about 31%.
After the implant removed, within 120 days of LNG
is not found again in circulation.27
The first time capsule Norplant® was developed in
1983, using a rigid tube. Since 1991 capsules have
been modified to be more delicate so as to release of
LNG per day a little more and were significantly
lower pregnancy rates.29
Effectiveness of Norplant® contraceptive and Ja-
delle® has been proven to be used up to 5 years43,
but clinical data suggests Norplant® was still effective
until year seven.44 Sino-implant®, LNG implant made
in China, similar Norplant® and Jadelle®, also showed
similar effective to the original.45
Implant Etonogestrel
Implanon® is a single rod implant containing etono-
gestel and effective used for 3 years. Etonogestrel (3-
keto-desogestrel) is the active metabolite of desoges-
trel. This implant is made from a mixture of steroids
with polymer ethylene vinyl acetate (EVA) to form a
rigid tube and wrapped by a thin membrane of EVA
on the outside. Etonogestrel maximum levels are
reached on day four after insertion, then levels are
declined slowly until the third year of use. Etonoges-
trel levels are also associated with weight, and etono-
gestrel is not immediately detected within one week
after implant removal.46
Implant Nestorone
Nestorone® implant (ST1435) consist of one rod, de-
veloped by the Population Council in the USA, and
is planned to be effective for 2 years. The same pro-
gestin studied in Brazil with the name Elcometrine®
is one capsule with a silicone implant effectiveness
for 6 months.27
Implant Nomegestrol Acetate
Uniplant a silicone implant a capsule containing no-
megestol acetate with an approximate effective for
one year. But until now it has not been marketed im-
plant.27
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Drug Release System of Implant
In the past three decades a research was developed to
determine the drug release control system in particular
to determine the effective levels of drugs in pharma-
cology. Drug release system control technology al-
ready very advanced, especially for oral medications
and transdermal. Especially for drugs that must be
given within a period of time with technology inser-
tion into the body, emerging issues of rejection of the
body (biocompatibility), especially about tissue rejec-
tion (tissue compatibility). The reaction is usually a
reaction of biocompatibility toxic, carcinogenic, im-
munogenic, and inflammation.47 Biocompatibility of
the body is related to implant materials (biomaterials)
used.48 Silicon, whether or methylvinylsiloxane dime-
thylsiloxane copolymer, has been used since 1950,
and is The most compatible biomaterials.47
Silastic tube (medical grade polydimethylsiloxane)
has been used in humans as an implant or implants
and other surgical equipment, and placed permanently
in the body, since 1950. For example, 200,000 cases
of hydrocephalus have been using tube silastik as
cerebrospinal fluid drainage throughout his life with-
out any serious reactions against foreign substances.
Similarly, medical glue (silicone type A) has been
long and widely used during surgery.47
After the implant is placed under the skin, tissue
rejection reaction (tissue compatibility) is triggered by
tissue damage during insertion. Local inflammatory
reaction occurs in the form of a series of rejection
reaction of neutrophil cells, polimorfonukleus, eusi-
nofil and macrophages. Next place the repair process
of damaged tissue in the form of granulation tissue.
Because the silastic tube is not digested by macro-
phage cells, the body through perivascular fibroblast
cells tend to isolate the tube to form a sheath or con-
nective tissue capsule around tube. Fibrous capsule
formation around the tube affects drug release pro-
cess, in addition to resulting in the tube is not easily
driven and difficult to be separated at the time of im-
plant removal.47
Since Folkman and Long (1964) found that silastic
tube can be used for distribution of drugs because it
can release the contents little by little; and Dziuk and
Cook in vitro proved that the drug is removed from
the tube silastic always in a constant concentration,
so Segal and Croxatto (1966) first tried to use that
silastic tube implanted under the skin as a system to
distribute the steroid hormone. This research became
the basis and concept development of long-term con-
traceptive that then we know as the implant or im-
plants.4,49,50
The first generation of implant Norplant®, consist-
ing of six capsules, containing LNG in a matrix of
silicone elastomer. Once inserted, Norplant® immedi-
ate release of LNG 50 - 80 μg/day. At the end of the
first year of use, LNG will be released around 40 -
50 μg/day, then will go down slowly to about 25 -
30 μg/day in the fifth year of use. However, Nor-
plant® showed success in preventing pregnancy for a
period of up to seven years, with a cumulative preg-
nancy rate of seven years is 1%.18,51
Further developed the second generation implant is
Jadelle® which only consists of two rods. Since using
the new elastomer technology to become more soft,
flexible, with a lower silicon content, the ability to
increase drug release. Therefore, two bars Jadelle®
has the ability to remove the same LNG as six capsule
Norplant®. Jadelle® in the first month of LNG re-
leased about 100 μg/day. Then dropped to about 40
μg/day until month 12 and settled about 30 μg/day at
month 24. Jadelle® has been approved for use during
the five-year cumulative pregnancy rate of five years
is 1%.26
Pharmacodynamic and Mechanism of Actions
Inhibition of Ovulation 
LNG is a synthetic progesterone which can prevent
pregnancy through several mechanisms work. The
main working mechanisms are inhibiting ovulation in
approximately 50% of the menstrual cycle.19,21,52 A
small amount of LNG that is released from the im-
plant will continuously work on the hypothalamus and
anterior pituitary gland. Furthermore, a decline in the
secretion of FSH (Follicle Stimulating Hormone) and
LH (Luteinizing Hormone). LNG will inhibit or re-
duce wave surge of LH (LH surge) in mid-cycle so
that ovulation is disturbed.53,54
Depend on the daily levels of LNG were released,
LNG cause follicle growth and ovulation processes,
ranging from ovulation or anovulation does not occur
until there luteal phase insufficiency. LNG is not
completely suppressing the secretion of estrogen.
Ovulation can be prevented or hindered only, so its
influence on the secretion of estrogen per cycle vary
widely.53 The mean levels of estrogen may still be
within the normal range of 280 pmol/ml, but some of
them could reach 1.5 nmol/ml.
Luteal phase of activity is generally not visible in
the first year of implant use, but began to increase in
the years following. If the activity seen lutael phase,
progesterone levels remained low was significantly
below normal levels. Luteal phase insufficiency is due
to the influence of FSH and LH pre-ovulatory and
mid-cycle LH surge is generally low and short. Use
of Norplant® progesterone levels lower than women
who did not use hormonal contraceptives. Low levels
of progesterone is due to mechanism of action of
LNG that suppress secretion of progesterone.53
Thickness of Cervical Mucus
Mechanism of action of LNG is another cause of cer-
vical mucus becomes cloudy and thick (within 24 -
48 hours after installation), making sperm penetration
disturbed,54-56 despite normal endogenous estrogen
levels or above normal.
Under the influence of endogenous or exogenous
progesterone, cervical mucus will become cloudy vis-
cous inelastic and non-transparent or opaque. This si-
tuation is similar to cervical mucus after menstrual
period ends, the exsternum ostium of uteri covered
by a thick mucus and acidic, making it impossible for
sperm to enter the uterus. The quality of mucus is
different from the circumstances surrounding the time
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of ovulation. At that time the mucus produced is more
watery and elastic because it has a higher water content,
more transparent or translucent, and less acidic.57
Croxatto (1993)58 said that although the LNG im-
plant of ovarian inhibition effect on several levels,
including anovulation and luteal insufficiency, caus-
ing irregular endometrial thickness is not dependent
on estrogen levels, but the main effect is to cause the
cervical mucus becomes thick and slightly because
antiestrogenic strong effect of LNG. Effect of sperm
penetration of these barriers is the sole antifertility
effect of Norplant®, even when circulating estradiol
levels comparable to those seen in the late follicular
phase of normal menstrual cycle or the cycle is still
ovulating.59
Suppress of Endometrium Growth
Mechanism of action of the other is to suppress en-
dometrial growth (hypoplasia) because LNG inhibits
progesterone work by occupying its receptors in the
endometrium. This mechanism causes the endometrial
cells lining the uterine cavity did not proliferate and
the glands become smaller. As a result, the endome-
trium becomes thin layer so it is not friendly and com-
plicate implantation.42,53,60
Monoplant®, the New Indonesian Implant
The Indonesian Implant
Around the year of 1999 Biomedicine Programme
Faculty of Medicine and Raden Saleh Clinic exam-
ined a prototype implant KB Indonesia in experimen-
tal animals. In the dorsal neck of an ape silicone-filled
implants medroxyprogesterone acetate powder was
implanted and the results were reported on a meeting
at WHO consultation KB implant in 2001.61
Indonesia always follows the development of this
implant technology, even is eager to develop and cre-
ate its own implant. Around the year of 2000 Indo-
nesia developed and examined an implant which con-
sists of 2 rods of LNG with an approximate effective
for 3-year period called Indoplant®, but the implant
has not been marketed because it is still in the re-
search phase 3 clinical trials.62,63
Monoplant®, the Single Rod Implant
Although some type of implant method in the world
has been marketed, but each type has advantages and
disadvantages, both effectiveness and side effects.
Therefore, efforts were made in finding the best kind
of kept doing particularly difficult to reduce com-
plaints and duration of insertion and removal. It was
attempted to develop implant comprising only one bar
that is named Monoplant®.
Indoplant® and Monoplant®, developed and pro-
duced by Indonesian Pharmacy, also uses the same
silastic elastomer tube with Jadelle®, contain 150 mg
of LNG to Indoplant® and 160 mg for Monoplant®.
Monoplant® implant only contains progestin in the
form of levonorgestrel. This implant consists of only
one flexible rod and in contains a mixture of the same
amount of LNG with silicone elastomer. Stem silicone
implant was wrapped with thin-walled tube (same as
used in Jadelle® or Jadena®), and on the edges closed
with a Silastic (polydimethyl-siloxane) Medical Grade
Adhesive. Each implant stem 43 - 44 mm long with
a diameter of 2.5 to 2.6 mm and contains 160 mg of
LNG as shown in Figure 1.15,64
The materials used to make implants Monoplant®
is not a new drug. LNG has been used for more than
30 years in both the pill for contraception (combina-
tion pills and minipil) and in the implant.64
Monoplant® is estimated to have effectiveness as
a contraceptive for 3 (three) years. Because of this
device is produced in Indonesia, the benefits to be
obtained is very effective for 3-year pairs, does not
require routine control, the price is cheaper so it is
relatively easy affordable and widely available in the
Center for Health Services, in addition to easy inser-
tion and removal as compared with the method An-
other implant that consists of more than one rod.
CONCLUSIONS
Implant began researched since 1966. It consists of
silicon as a tube, and contains a progestin elastomers
as bioactive materials. Since 1983 the first generation
implant Norplant® 6 capsule, containing LNG, mar-
keted. As a long-term contraceptive method that is
placed under the skin, silicone tube and progestin are
used up to now has been proven safe.
Although there has been researches on develop-
ment of several implants with a different progestin,
WHO recommends that only next-generation implant
Jadelle® two rods and Implanon® single rod to be
marketed and used.
As a country with the largest number of implant
acceptors, Indonesia is also developing Indoplant® 2
rods implant and the last Monoplant® single rod im-
plant. Both implant is effective for at least 3 years.
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